Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT00513305

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00513305. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years of age) with acute myeloid leukemia.

Study identification

NCT ID: NCT00513305
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Cephalon; Industry
Enrollment: 67 participants

Conditions and interventions

Conditions

Acute Myeloid Leukemia

Interventions

Arsenic trioxide Drug
Low-dose cytarabine alone Drug

Drug

Eligibility (public fields only)

Age range: 60 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2007 (Type not available)
Primary completion: Jul 2009 (Actual)
Completion: Dec 2009 (Actual)
Last update posted: Aug 1, 2012

2007 – 2009

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
USC / Norris Cancer Hospital	Los Angeles	California	90033	—
UCLA Medical Center	Los Angeles	California	90095	—
University of Illinois	Chicago	Illinois	60612	—
Indiana Oncology Hematology Consultants	Indianapolis	Indiana	46202	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
St. Vincent's Comprehensive Cancer Center	New York	New York	10011	—
Weill Medical College of Cornell University	New York	New York	10021	—
Brody School of Medicine	Greenville	North Carolina	27834	—
University of Oklahoma	Oklahoma City	Oklahoma	73104	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
UT Health Science Center	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00513305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 1, 2012 · Synced Nov 14, 2026